Protalix Biotherapeutics, INC 8-K filings

Protalix BioTherapeutics announces significant revenue growth and profitability for Q2 2026, driven by Elfabrio sales and a milestone payment, while advancing its PRX-115 clinical trial.

Protalix BioTherapeutics stockholders elected eight directors and approved an increase in shares for the 2006 Stock Incentive Plan.

Protalix BioTherapeutics posted a corporate presentation on May 21, 2026, highlighting regulatory milestones, pipeline advancements, and financial strength.

Protalix BioTherapeutics reported strong Q1 2026 results, driven by a $25 million milestone payment from Chiesi for Elfabrio, and reaffirmed its full-year revenue guidance.

Protalix BioTherapeutics announced a positive CHMP opinion for Elfabrio's expanded dosing in the EU and provided updates on its rare disease pipeline and financial outlook.

Protalix BioTherapeutics and Chiesi Global Rare Diseases received a positive CHMP opinion for an every-four-week dosing regimen of Elfabrio for Fabry disease in the EU, potentially reducing patient burden.

Protalix BioTherapeutics provided a stockholder update detailing consistent commercial performance of Elfabrio, advancement of PRX-115 for uncontrolled gout, and a new strategic focus on rare kidney diseases.

Protalix BioTherapeutics announced its third quarter 2025 financial results, showing a 24% year-to-date revenue increase despite a slight Q3 dip, alongside key pipeline advancements and a European regulatory challenge for Elfabrio.

Protalix BioTherapeutics and Chiesi Global Rare Diseases have requested a re-examination of the EMA's negative opinion regarding an alternative dosing regimen for their Fabry disease treatment, Elfabrio.

The European Medicines Agency's CHMP issued a negative opinion on Protalix BioTherapeutics' request to approve an every-four-week dosing regimen for its Fabry disease treatment, Elfabrio.

Protalix BioTherapeutics amended its At-The-Market offering agreement, enabling the sale of up to $20 million in common stock under a new S-3 registration.

Protalix BioTherapeutics reported a net income of $164,000 for Q2 2025, driven by a 16% increase in revenues from selling goods, primarily Elfabrio.

Protalix BioTherapeutics, Inc. announced the dismissal of a shareholder class action lawsuit after amending its bylaws and agreeing to pay legal fees.

Protalix BioTherapeutics, Inc. announced the appointment of Gilad Mamlok as its new Senior Vice President and Chief Financial Officer, effective August 24, 2025, following the resignation of Eyal Rubin.

Protalix BioTherapeutics, Inc. announced the successful adoption of all proposals at its 2025 Annual Meeting of Stockholders, including the re-election of its eight nominated directors, advisory approval of executive compensation, and ratification of its independent accounting firm.

Protalix BioTherapeutics announces a significant increase in first quarter revenue and provides updates on its clinical pipeline, including progress on its gout treatment candidate.

Eyal Rubin, CFO of Protalix BioTherapeutics, has announced his resignation, effective in six months, to pursue other opportunities.

Protalix BioTherapeutics increases its at-the-market offering by $20 million to raise capital for general corporate purposes, including working capital and funding clinical trials.

Protalix BioTherapeutics announces strong financial results for 2024, driven by increased product sales, and provides updates on its clinical pipeline, including positive early results for its gout treatment candidate.

Protalix BioTherapeutics has amended its bylaws, increasing the ownership threshold for stockholders to call special meetings and modifying procedures for proposals and director nominations.

Protalix BioTherapeutics highlighted its 2024 accomplishments, including progress in clinical trials, sales growth, and debt repayment, while outlining its strategic focus for 2025.

Protalix BioTherapeutics reports encouraging preliminary results from its Phase 1 trial of PRX-115 for gout and a 75% increase in product revenue for the third quarter of 2024.

Protalix BioTherapeutics will present Phase I clinical trial data for its PRX-115 gout treatment at the American College of Rheumatology Convergence 2024.

Protalix BioTherapeutics reported a decrease in revenue and a net loss for the second quarter of 2024, while also highlighting progress in its clinical pipeline.

Protalix BioTherapeutics held its 2023 Annual Meeting of Stockholders, where key proposals including the election of directors and amendments to the stock incentive plan were approved.

Protalix BioTherapeutics reported positive initial results from its PRX-115 clinical trial, alongside a decrease in first quarter revenue compared to the previous year.

Protalix BioTherapeutics announced its fiscal year 2023 financial results, highlighted by regulatory approvals for Elfabrio and a significant increase in revenue.